Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin
January 10 2019 - 8:30AM
Daxor Corporation
(NYSE MKT: DXR), an investment
company with innovative medical instrumentation and biotechnology
operations focused on blood volume measurement, today announces
that Aspirus Wausau Hospital in Wausau Wisconsin has acquired a
BVA-100 Blood Volume Analyzer.
Best known for its world-class cardiovascular
program, Aspirus Wausau Hospital also provides leading edge cancer,
trauma, women’s health, and spine and neurological care. Aspirus
Wausau Hospital is the flagship of the Aspirus system that serves
patients in 14 counties across northern and central Wisconsin, as
well as the Upper Peninsula of Michigan. It is licensed for 325
beds and staffed by 350 physicians in 35 specialties.
The hospital is continually recognized
nationally for the level of care it provides. Aspirus Wausau
Hospital has earned high quality ratings or awards from prominent
quality agencies such as HealthGrades, Thomson Reuters, Truven
Health, Becker’s Hospital Review, Mission: Lifeline® and U.S. News
& World Report.
“We look forward to partnering with Aspirus
Hospital to integrate blood volume analysis as standard of care by
providing clinicians with rapid, accurate and actionable
information to inform better treatment strategies not only in heart
failure, but in a wide variety of surgical and medical conditions,”
said Michael Feldschuh, CEO of Daxor Corporation. “Objective
measurement of volume status and composition enables
individualization of treatment to ensure better outcomes for
patients and better quality of life.”
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the only clinically available, rapid
and accurate diagnostic to provide rapid direct measurement of a
patient’s blood volume. We believe that the BVA-100 Blood Volume
Analyzer has the potential to transform therapy in a broad range of
surgical and medical conditions. It is our goal, working in
conjunction with hospitals and clinics, to achieve that
possibility. Ultimately the company’s mission is to help hospitals
and physicians incorporate Daxor’s BVA-100 diagnostic to
significantly improve the quality of patient care. For more
information please visit our website at http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE
IR561-479-8566brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024